Clinical Trial

Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 31, 2024 (before its estimated April 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
Subjects with biopsy-proven NASH will be randomly assigned in a 2:1 ratio to oral doses of namodenoson 25 mg every 12 hours or matching placebo every 12 hours for 36 weeks. Subjects will be evaluated regularly for safety, and efficacy biomarkers will be measured at Baseline and Weeks 6, 12, 24, and 36. At Week 36, all subjects will undergo liver biopsy.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT04697810
Lead Sponsor Can-Fite BioPharma
Conditions NASH - Nonalcoholic Steatohepatitis
Enrollment 114 participants
Start Date 2021-12-10
Primary Completion 2025-04-15 (estimated)
Study Completion 2025-10-15 (estimated)
Updated on ClinicalTrials.gov 2024-07-31